Parnax Lab

Parnax Lab Deferred Tax Liabilities

The Deferred Tax Liabilities of Parnax Lab (506128.BO) as of Nov 13, 2026 is 53.67 M INR. In the previous year, Deferred Tax Liabilities was 46.86 M INR — a change of 14.53% (higher).

Deferred Tax Liabilities

53.67 MINR

YoY

14.53%

Last updated:

Deferred Tax Liabilities of Parnax Lab is 2025 53.67 M INR. Deferred Tax Liabilities of Parnax Lab was 2024 46.86 M INR. It decreases by 14.53% higher compared to the previous year.

The Parnax Lab Deferred Tax Liabilities history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Deferred Tax Liabilities
Date
Deferred Tax Liabilities
Jan 1, 2018
6.75 M INR
Jan 1, 2019
7.12 M INR
Jan 1, 2020
16.89 M INR
Jan 1, 2021
18.74 M INR
Jan 1, 2022
31.67 M INR
Jan 1, 2023
39.28 M INR
Jan 1, 2024
46.86 M INR
Jan 1, 2025
53.67 M INR
The Parnax Lab Deferred Tax Liabilities history
YEARDeferred Tax LiabilitiesYoY
53.67 MINR+14.53%
46.86 MINR+19.31%
39.28 MINR+24.03%
31.67 MINR+68.94%
18.74 MINR+10.96%
16.89 MINR+137.29%
7.12 MINR+5.43%
6.75 MINR+247.26%
1.94 MINR-60.08%
4.87 MINR-42.69%
8.50 MINR-28.57%
11.90 MINR—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Parnax Lab Stock analysis

What does Parnax Lab do? Parnax Lab Ltd. generates revenue through manufacturing and exporting pharmaceutical formulations, including cough expectorants, antacids, anti-histamines, multi-vitamins, enzyme preparations, pediatric formulations, geriatric special formulations, highly viscous products, and suspensions. The company trades pharmaceuticals and medicinal products, focusing on high-volume oral formulations for diverse consumer segments. Naxpar Pharma Private Limited serves as its subsidiary in these operations. The firm's primary customers are likely healthcare providers, pharmacies, and distributors within the pharmaceutical industry, though specific buyer details are not disclosed. Parnax Lab Ltd. operates through the pharmaceutical formulations segment, emphasizing export-driven manufacturing and trading activities. Its product portfolio targets various health needs, from pediatric to geriatric care, with a strong focus on oral delivery systems. Parnax Lab is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Parnax Lab stock

Deferred Tax Liabilities of Parnax Lab is 53.67 M INR in 2025.

Deferred Tax Liabilities of Parnax Lab changed from 46.86 M INR to 53.67 M INR, representing a 14.53% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Deferred Tax Liabilities Parnax Lab since 2006 – with annual values, charts, and detailed analysis.

Deferred tax liabilities arise from temporary differences between accounting and tax treatments. They represent taxes owed in the future on income already recognized.

Deferred Tax Liabilities's INR is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Deferred Tax Liabilities's Parnax Lab historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Balance Sheet — Parnax Lab

All Key Metrics — Parnax Lab